Dr. Reddy’s has launched Toripalimab, a novel immuno-oncology drug, in India for treating recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Toripalimab, already approved by USFDA and EMA, will be marketed as Zytorvi. It shows significant efficacy in combination with chemotherapy drugs gemcitabine and cisplatin, and also as monotherapy for patients with disease progression.
